|
|
Infectious Diseases
Research Funding
(listed alphabetically by Principal Investigator or by Section faculty member involved)
2006-2008
International Maternal Pediatric Adolescent AIDS Clinical Trials Group
Principal Investigator: Mark J. Abzug, MD
Source: NICHD, NIH - BRS-IMPCT-Q-06-00116-T00
Amount: $2,450/yr
Term: 2006 - 2007
NIH Collaborative Antiviral Study Group: A Double-Blind, Placebo-Controlled, Virologic Efficacy Trial of Pleconaril in the Treatment of Neonates with Enterovirus Sepsis Syndrome
Principal Investigator: Mark J. Abzug, MD
Source: NIAID, NIH - N01-A1-30025
Amount: Per patient enrolled
Term: 1999 - ongoing
NIH Collaborative Antiviral Study Group: A Pharmacokinetic/Pharmacodynamic and Safety Evaluation of Oseltamivir for the Treatment of Children <24 Months of Age with Confirmed Influenza Infection
Principal Investigator: Mark J. Abzug, MD
Source: NIAID, NIH - N01-AI-30025
Amount: Per patient enrolled
Term: 2007 - ongoing
NIH Collaborative Antiviral Study Group: Phase 3 Randomized, Placebo-Controlled Blinded Investigation of 6 Weeks vs. 6 Months of Oral Valganciclovir in Infants with Symptomatic Congenital Cytomegalovirus Infection
Principal Investigator: Mark J. Abzug, MD
Source: NIAID, NIH - N01-AI-30025
Amount: Per patient enrolled
Term: 2007 - ongoing
NIH Collaborative Antiviral Study Group: Retrospective Chart Review to Assess the Safety of Oseltamivir Compared to Alternate Antiviral Therapy Administered to Children Less than 12 Months of Age
Principal Investigator: Mark J. Abzug, MD
Source: NIAID, NIH - N01-AI-30025
Amount: $1720
Term: 2006 - 2008
Treatment of Clogged Tympanostomy Tubes: An Off-Label Use of Dornase Alfa (Pulmozyme)
Principal Investigator: Kenny Chan, MD
Co-Investigator: Mark J. Abzug, MD
Source: Genentech, Inc.
Amount: Per patient enrolled
Term: 2006 - ongoing
Fever and Neutropenia in Pediatric Oncology Patients: A Randomized, Controlled, Multicenter Study of Outpatient Therapy and Evaluation of Genomic and Proteomic Correlates
Principal Investigator: Sue Lindemulder, MD
Consultant: Mark J. Abzug, MD
Source: St. Baldrick's Foundation Grant
Amount: $18,600/yr
Term: 2006 - 2008
Fever and Neutropenia in Pediatric Oncology Patients: A Randomized, Controlled, Multicenter Study of Outpatient Therapy and Evaluation of Genomic and Proteomic Correlates
Principal Investigator: Sue Lindemulder, MD
Consultant: Mark J. Abzug, MD
Source: Pediatric Clinical Translational Research Center Pilot and Feasibility Program Grant
Amount: $19,880/yr
Term: 2006 - 2008
Hematology Oncology Fellowship Program Grant: Fever and Neutropenia in Pediatric Oncology Patients
Principal Investigator: Sue Lindemulder, MD
Consultant: Mark J. Abzug, MD
Source: Amgen Inc.
Amount: $40,000/yr
Term: 2006 - 2007
Safety of Ciprofloxacin in Pediatric Patients
Principal Investigator: Marsha S. Anderson, MD
Source: Bayer Corporation
Amount: Per patient enrolled
Term: 2001 - 2007
Phase III, Open-Label, Randomized, Multicenter Study to Evaluate Safety and Immunogenicity of Novartis Meningococcal ACWY Conjugate Vaccine Administered with Routine Infant Vaccinations (Infants)
Principal Investigator: Marsha S. Anderson, MD
Co-Principal Investigator: Mary P. Glodé, MD
Source: Novartis AG
Amount: Per patient enrolled
Term: 2007 - 2009
Phase III Randomized, Multicenter Study to Evaluate Lot-to-Lot Consistency of Novartis Meningococcal ACWY Conjugate Vaccine and to Evaluate Safety and Immunogenicity in Adolescents 11-18 Years
Principal Investigator: Marsha S. Anderson, MD
Co-Principal Investigator: Mary P. Glodé, MD
Source: Novartis AG
Amount: Per patient enrolled
Term: 2007 - 2009
Region VIII Center for Excellence for Biodefense and Emerging Infectious Diseases: Education and Outreach Subproject
Principal Investigator (Subproject): Marsha S. Anderson, MD
Co-Principal Investigator: Ann-Christine Nyquist, MD, MPH
Source: NIAID, NIH - U54-AI-065357
Amount: $434,404
Term: 2005 - 2009
Epidemiology and Pathogenesis of Novel Coronaviruses
Principal Investigator: Samuel R. Dominguez, MD, PhD
Source: TCH Research Institute
Amount: $30,000/yr
Term: 2007 - 2008
Epidemiology and Pathogenesis of Novel Coronaviruses
Principal Investigator: Samuel R. Dominguez, MD, PhD
Consultant: Mark J. Abzug, MD
Source: NIAID, NIH - 1K08AI073525-01A1
Amount: $122,500/yr
Term: 2008 - 2013
Mentored Clinical Scientist Research Career Development Award: Epidemiology and Pathogenesis of Novel Coronaviruses
Principal Investigator: Samuel R. Dominguez, MD, PhD
Source: NIAID, NIH - 1 K08 AI073525-01A1
Amount: $132,220/yr
Term: 2008 - 2013
Pediatric Infectious Disease Society Fellowship Award: Virus Entry and Clinical Significance of the Newly Discovered Human Coronaviruses
Principal Investigator: Samuel R. Dominguez, MD, PhD
Source: Roche Laboratories - CoV-NL63
Amount: $30,000/yr
Term: 2005 - 2007
Specialized Biodefense Training Clinical/Translational: Epidemiology and Characterization of Novel Rocky Mountain Bat Coronaviruses
Principal Investigator: Samuel R. Dominguez, MD, PhD
Source: NIAID, NIH - U54-AIO65367
Amount: $117,170/yr
Term: 2007 - 2008
Phase III Open-label, Nonrandomized International Multicenter Trial to Evaluate Efficacy and Safety of Cardiolite Myocardial Perfusion and Imaging in Pediatric Subjects with Kawasaki Disease
Principal Investigator: Mary P. Glodé, MD
Source: Bristol-Myers Squibb
Amount: Per patient enrolled
Term: 2006 - 2016
Atopic Dermatitis and Vaccinia Immunization Network
Principal Investigator: Myron J. Levin, MD
Source: National Jewish Hospital, NIAID, NIH - HHSN266200400029C
Amount: $105,092
Term: 2004 - 2008
A Double-Blind, Randomized, Controlled Phase III Study to Assess the Prophylactic Efficacy and Safety of bD-Alum/MPL Vaccine in the Prevention of Genital Herpes Diseases in Young Women Who are HSV-1 and -2 Seronegative
Principal Investigator: Myron J. Levin, MD
Source: St. Louis University/GlaxoSmithKline, NIAID, NIH - N01-AI-45250
Amount: $1,942,420
Term: 2002 - 2011
International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT)
Principal Investigator: Myron J. Levin, MD
Source: Social and Scientific Systems (SSS), NIAID, NIH - BRS-Q-06-00116-T002
Amount: $109,916
Term: 2006 - 2013
International Pediatric and Perinatal HIV Studies Network
Principal Investigator: Myron J. Levin, MD
Co-Principal Investigator: Elizabeth J. McFarland, MD
Co-Investigators: Adriana Weinberg, MD, Mark J. Abzug, MD, Robin E. McEvoy, PhD, Suzanne M. Paul, BSN, FNP-C, and Amy Witte, RN, MSN, FNP-C
Source: Westat, NICHD, NIH - N01-HD-3-3345
Amount: $7,008,031
Term: 2002 - 2007
Monitor Subjects Who Originally Received Herpes Zoster Vaccine to Monitor the Durability of the Vaccine
Principal Investigator: Myron J. Levin, MD
Source: Veteran Administration Connecticut Research & Education Foundation (VACREF), Merck - CSP 403C
Amount: $752,088
Term: 2005 - 2010
A Multicenter, Randomized, Double-Blind Study to Compare the Efficacy and Safety of Patient-Initiated Famiciclovir 1000 mg b.i.d. x 1 day to Valacyclovir 500 mg b.i.d. x 3 Days in Immunocompetent Adults with Recurrent Genital Herpes
Principal Investigator: Myron J. Levin, MD
Source: Novartis AG - CFAM810A-A2308
Amount: $94,544
Term: 2006 - 2010
NICHD International and Domestic Pediatric and Maternal HIV Studies Coordinating Center
Principal Investigator: Myron J. Levin, MD
Co-Investigator: Mark J. Abzug, MD
Source: Westat, NICHD, NIH - N01-DK-8-0001
Amount: $1,312,107
Term: 2007 - 2012
NICHD International and Domestic Pediatric and Maternal HIV Studies Coordinating Center
Principal Investigator: Myron J. Levin, MD
Co-Principal Investigator: Elizabeth J. McFarland, MD
Co-Investigators: Adriana Weinberg, MD, Mark J. Abzug, MD, Emily A. Barr, CPNP, CNM, Robin E. McEvoy, PhD, Suzanne M. Paul, BSN, FNP-C, and Amy Witte, RN, MSN, FNP-C
Source: Westat, NICHD, NIDDK, NIH - N01-DK-8-0001
Amount: $7,315,975
Term 2007 - 2012
A Phase I, Double-Blind, Randomized, Placebo-Controlled, Multicenter Clinical Trial to Evaluate the Safety and Immunogenicity of V21/Heat-Treated Varicella-Zoster Virus (ZVZ) Vaccine in Immumncompromised Adults
Principal Investigator: Myron J. Levin, MD
Source: Merck Research Laboratories, Merck & CO., Inc.
Amount: $131,784
Term: 2007 - 2009
A Phase I/II, Double-Blind, Randomized, Controlled, Dose-Range Study to Assess the Safety/Immunogenicity of an HPV-16/18/31/45 VLP/AS04 Vaccine when Administered Intramuscularly
Principal Investigator: Myron J. Levin, MD
Source: GlaxoSmithKline - 102115
Amount: $82,550
Term: 2005 - 2009
A Phase II, Dose-Finding Study with ASP2151 in Subjects with Recurrent Episodes of Genital Herpes
Principal Investigator: Myron J. Levin, MD
Source: Astellas Pharma U.S., Inc. - 200705-280
Amount: $225,321
Term: 2007 - 2011
A Phase III Clinical Trial to Evaluate the Efficacy, Immunogenicity, Safety, and Tolerability of ZOSTAVAX in Subjects 50 to 59 Years of Age, V211-022
Principal Investigator: Myron J. Levin, MD
Source: Merck Research Laboratories, Merck & CO., Inc.
Amount: $175,015
Term: 2007 - 2010
A Phase III Clinical Trial to Study the Safety, Tolerability, and Immunogenicity of Zoster Vaccine Live (Oka/Merck) in Subjects with a History of Herpes Zoster
Principal Investigator: Myron J. Levin, MD
Source: Merck Research Laboratories, Merck & Co., Inc. - V211-014
Amount: $16,198
Term: 2006 - 2009
A Phase III, Double-Blind, Randomized, Controlled Study to Evaluate the Safety, Immunogenicity, and Efficacy of Glaxo-Smith Kline Biologicals’ HPV-26/28 L1/AS04 Vaccine Administered Intramuscularly
Principal Investigator: Myron J. Levin, MD
Source: GlaxoSmithKline - 104820
Amount: $66,750
Term: 2006 - 2009
A Phase IIIB, Observer-Blind, Randomized, Multicenter Study with Two Parallel Groups to Compare the Immunogenicity of GSK Biologicals HPV-16/18 L1/AS04 Versus Merck’s Gardasil(R) Vaccine when Administered Intramuscularly According to a 3-Dose Schedule in Healthy Adult Females 18-45 Years of Age
Principal Investigator: Myron J. Levin, MD
Source: GlaxoSmithKline - HPV108933/010
Amount: $86,813
Term: 2007 - 2010
A Randomized, Double-Blind, Active-Controlled, Vehicle-Controlled, Subject-Initiated Study Comparing Efficacy and Safety of ME-609 Versus Acyclovir Cream for Treatment of Recurrent Herpes Simplex Labialis
Principal Investigator: Myron J. Levin, MD
Source: Medivir - ME 609
Amount: $86,730
Term: 2006 - 2009
Retrospective Study That Would Evaluate Asthmatic Children Who Had Already Received Varivax® in the Past
Principal Investigator: Myron J. Levin, MD
Source: Merck Research Laboratories, Merck & Co., Inc.
Amount: $69,000
Term: 2003 - 2006
Ryan White Part D HIV Program for Children, Youth, Women, and Families
Principal Investigator: Myron J. Levin, MD
Co-Principal Investigator: Elizabeth J. McFarland, MD
Investigator: Adriana Weinberg, MD
Source: Maternal and Child Health Bureau, HRSA, HHS, - H12HA00070
Amount: $885,272/yr
Term: 2004 - 2007
Ryan White Part D HIV Program for Children, Youth, Women, and Families
Principal Investigator: Myron J. Levin, MD
Co-Principal Investigator: Elizabeth J. McFarland, MD
Investigator: Adriana Weinberg, MD
Source: Maternal and Child Health Bureau, HRSA, HHS - H12HA00070
Amount: $936,325/yr
Term: 2007 - 2012
University of Colorado Center for AIDS Research
Principal Investigator: Thomas Campbell, MD
Co-Principal Investigator: Myron J. Levin, MD
Source: NIAID, NIH - P30 AI054907
Amount: $7,946,900
Term: 2003 - 2008
Comprehensive Resources and Counseling Services for People with HIV
Principal Investigator: Elizabeth J. McFarland, MD
Source: Colorado Department of Public Health and Environment
Amount: $63,074/yr
Term: 2007 - 2009
Evaluation of Programmed Cell Death-1 (PD-1) Expression and Multifunctional HIV-Specific T Lymphocytes in Infants and Children with HIV Infection
Principal Investigator: Elizabeth J. McFarland, MD
Source: Colorado Center for AIDS Research (CFAR) Developmental Projects
Amount: $25,000/yr
Term: 2007 - 2009
Implementation of Rapid HIV Testing at Denver Metro Labor and Delivery Sites
Principal Investigator: Elizabeth J. McFarland, MD
Source: Colorado Department of Public Health and Environment
Amount: $100,231
Term: 2007 - 2009
International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT)
Principal Investigator: Elizabeth J. McFarland, MD
Source: Social and Scientific Systems (SSS), NIAID, NIH - BRS-Q-06-00116-T001
Amount: $71,381
Term: 2006 - 2013
Pediatric HIV/AIDS Cohort Study (AMP Study)
Principal Investigator: Elizabeth J. McFarland, MD
Source: NICHD, NIH, Harvard - U01-HD052102
Amount: $390,000
Term: 2008 - 2010
Pediatric HIV/AIDS Cohort Study (PHACS) Clinical Site (SMARTT Study)
Principal Investigator: Elizabeth J. McFarland, MD
Co-Investigators: Emily A. Barr, CPNP, CNM, and Robin E. McEvoy, PhD
Source: NICHD, NIH, Harvard - U01-HD052102
Amount: $1,150,000
Term: 2006 - 2010
Ryan White Part A Funds for HIV Care: Outpatient Ambulatory Medical Care and Pharmaceutical Assistance and Mental Health
Principal Investigator: Elizabeth J. McFarland, MD
Source: Mayor's Office of HIV Resources, HRSA, Ryan White Part A
Amount: $236,794
Term: 2008 - 2009
Ryan White Part B: First Care/Retention in Care
Principal Investigator: Elizabeth J. McFarland, MD
Source: Colorado Department of Public Health and Environment
Amount: $84,000
Term: 2007 - 2009
Ryan White Part B: HIV Supplemental Funding for Medical Care and Behavioral Health and Psychosocial Support
Principal Investigator: Elizabeth J. McFarland, MD
Source: Colorado Department of Public Health and Environment
Amount: $109,439
Term: 2009 - 2010
Ryan White Title I Funds for HIV Care: Primary Health Care and Drug Reimbursement
Principal Investigator: Elizabeth J. McFarland, MD
Source: Mayor's Office of HIV Resources, HRSA Ryan White Title 1
Amount: $274,347
Term: 2006 - 2008
Center for AIDS Research Pharmacy Supplement
Principal Investigator: Courtney Fletcher, PharmD
Co-Investigator: Elizabeth J. McFarland, MD
Source: NIAID, NIH - 5P30 AI054907-04
Amount: $350,002
Term: 2004 - 2007
Impact of Exclusive vs. Mixed Breast Feeding on Susceptibility of Infants to HIV Infection
Principal Investigator: Edward Janoff, MD
Co-Investigator: Elizabeth J. McFarland, MD
Source: Elizabeth Glaser Pediatric AIDS Foundation
Amount: $200,000
Term: 2008 - 2010
Idiopathic Thrombocytopenic Purpura (ITP) After Live Virus and Influenza Vaccines: A Multicenter Retrospective Cohort Study
Principal Investigator: Jason Glanz, PhD
Co-Principal Investigator: Sean O’Leary, MD
Source: FDA
Amount: $1,041,000
Term: 2008 - 2010
Construction and Phenotypic Assessment of Mycobacterial Phospholipase A Deletion Mutants
Principal Investigator: Sarah K. Parker, MD
Source: Potts Memorial Foundation - 200709-039
Amount: $32,000
Term: 2007 - 2008
Construction and Phenotypic Assessment of Mycobacterial Phospholipase A Deletion Mutants
Principal Investigator: Sarah K. Parker, MD
Source: TCH Research Institute
Amount: $70,000/yr
Term: 2007 - 2009
Investigation of Mycobacterium Tuberculosis Phospholipase A Cell Wall Activity
Principal Investigator: Sarah K. Parker, MD
Source: American Lung Association
Amount: $40,000/yr
Term: 2008 - 2010
Phospholipases in the Pathogenesis of Mycobacterium Tuberculosis
Principal Investigator: Sarah K. Parker, MD
Source: NIAID, NIH - 5 K08 AI050646-05
Amount: $125,280
Term: 2002 - 2008
Determination of Sensitive Methods for Detecting Respiratory Virus Infections in Respiratory Tract Secretions
Principal Investigator: Eric A. Simões, MB, BS, DCH, MD
Source: Bill & Melinda Gates Foundation - 2581081
Amount: $265,977
Term: 2008 - 2010
Pneumo-Accelerated Development and Introduction Plan (ADIP)
Principal Investigator: Eric A. Simões, MB, BS, DCH, MD
Source: Johns Hopkins University - 2580754
Amount: $25,000
Term: 2005 - 2009
Zoonotic Avian Influenza: The Human-Animal Interface in the U.S. and Asia
Co-Principal Investigator: Eric A. Simões, MB, BS, DCH, MD
Source: CDC - 2580805
Amount: $485,000/yr
Term: 2006 - 2009
Atopic Dermatitis and Vaccinia Network (ADVN) Biomarker Registry Study
Principal Investigator: Adriana Weinberg, MD
Source: NIAID, NIH - N01-AI-40029
Amount: $80,711/yr
Term: 2007 - 2009
Critical Aspects of Successful Management of HIV Infection During Pregnancy
Principal Investigator: Adriana Weinberg, MD
Source: Abbott Laboratories - IIS-USAV-05-020
Amount: $35,973
Term: 2005 - 2009
Dendritic Cell Co-Infection with HIV and CMV
Principal Investigator: Adriana Weinberg, MD
Source: NIAID, NIH, and Colorado Center for AIDS Research - 5P30 AI054907
Amount: $25,000/yr
Term: 2007 - 2008
HSV Susceptibility to ASP2151
Principal Investigator: Adriana Weinberg, MD
Source: Astellas Pharma US, Inc.
Amount: $782,135
Term: 2007 - 2009
Incidence of hMPV in Lung Transplant Recipients
Principal Investigator: Adriana Weinberg, MD
Source: MedImmune, Inc. - SYN092-04d
Amount: $39,279
Term: 2005 - 2009
Influenza A and B Respiratory Specimens Acquisition
Principal Investigator: Adriana Weinberg, MD
Source: BD Diagnostics, Inc.
Amount: $40,413
Term: 2007 - 2010
International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT):
Immunology Core Laboratory
Principal Investigator: Adriana Weinberg, MD
Co-Principal Investigator: Elizabeth J. McFarland, MD
Source: NICHD, NIH - N01-HD-33162
Amount: $300,000/yr
Term: 2007 - 2012
Kinetics of Viral Shedding and Immunologic Responses to the Cold-Adapted Influenza Vaccine
Principal Investigator: Adriana Weinberg, MD
Source: MedImmune, Inc. - CAIV-T
Amount: $135,645
Term: 2006 - 2009
Mechanisms of Protection of Varicella-Zoster Virus Infection Against Glioblastoma
Principal Investigator: Adriana Weinberg, MD
Source: National Cancer Institute, NIH - P30 CA046934
Amount: $20,000/yr
Term: 2008 - 2009
Reconstitution of Protective CMV Immunity and Immune Regulation After HAART
Principal Investigator: Adriana Weinberg, MD
Source: NIAID, NIH - 1R21AI073121-01A2
Amount: $125,000/yr
Term: 2007 - 2009
RSV and PIV Immunology Pilot
Principal Investigator: Adriana Weinberg, MD
Source: MedImmune, Inc.
Amount: $187,562/yr
Term: 2005 - 2009
Type 1 Diabetes TrialNet Study
Principal Investigator: Adriana Weinberg, MD
Source: NIDDK, NIH - U01 DK61055
Amount: $385,750/yr
Term: 2003 - 2012
Epidemiology of Adult Glioma
Principal Investigator: Margaret Wrensch, MD
Co-Investigator: Adriana Weinberg, MD
Source: National Cancer Institute, NIH - R01 CA52689
Amount: $14,009/yr
Term: 1997 - 2012
2005
A Double-Blind, Placebo-Controlled, Virologic Efficacy Trial of Pleconaril (VP63843) in the Treatment of Neonates with EV Sepsis Syndrome (Protocol Version 2.0/Version Date 4/25/99)
Principal Investigator: Mark J. Abzug, MD
Source: National Institute of Allergy and Infectious Disease Collaborative Antiviral Study Group, National Institutes of Health
Amount: Per patient enrolled
Term: 1999-ongoing
Region VIII Center for Excellence for Biodefense and Emerging Infectious Diseases: Education and Outreach Subproject
Principal Investigator (Subproject): Marsha S. Anderson, MD
Source: National Institutes of Health
Amount: $688,953
Term: 2005-2009
Safety of Ciprofloxacin in Pediatric Patients
Principal Investigator: Marsha S. Anderson, MD
Source: Bayer Corporation
Amount: Per patient
Term: 2001-present
Apoptotic Signaling in Viral Myocarditis
Principal Investigator: Roberta L. DeBiasi, MD
Source: National Institutes of Health Physician Scientist Award - 1 K08 A152261-01
Amount: $604,800
Term: 2002-2007
A Double-Blind, Randomized, Controlled Phase III Study to Assess the Prophylactic Efficacy and Safety of Bd-Alum/MPL Vaccine in the Prevention of Genital Herpes Diseases in Young Women Who Are HSV-1 and -2 Seronegative
Principal Investigator: Myron J. Levin, MD
Source: National Institute of Allergy and Infectious Disease and St. Louis University/GlaxoSmithKline
Amount: $974,693/yr
Term: 2002-2006
University of Colorado Center for AIDS Research
Principal Investigator: Robert Schooley, MD
Co-Principal Investigator: Myron J. Levin, MD
Source: National Institute of Allergy and Infectious Disease
Amount: $7,946,900
Term: 2003-2008
Study of the Safety and Efficacy of an Iontophoretic Device to Treat Recurrent Herpes Labialis
Principal Investigator: Myron J. Levin, MD
Source: Klearsen Corporation
Amount: $7,946,900
Term: 2003-2005
Pediatric and Perinatal HIV Clinical Trials
Principal Investigator: Myron J. Levin, MD
Co-Investigator: Elizabeth J. McFarland, MD
Source: Westat and National Institutes of Health, National Institute of Child and Human Development - N01-HD-3-3162
Amount: $5,010,161
Term: 2002-2007
Expansion of Pediatric ACTU
Principal Investigator: Myron J. Levin, MD
Co-Investigator: Adriana Weinberg, MD
Source: National Institute of Childhood Diseases - U0132915-05
Amount: $4,156,500
Term: 1996-2007
Retrospective Study That Would Evaluate Asthmatic Children Who Had Already Received Varivax® in the Past
Principal Investigator: Myron J. Levin, MD
Source: Merck Research Laboratories
Amount: $69,000
Term: 2003-2006
Rocky Mountain Regional Center for Excellence Clinical Training Grant
Principal Investigator: Ann-Christine Nyquist, MD, MSPH
Source: National Institutes of Health
Amount: $492,535
Term: 2005-2009
Phospholipases in the Pathogenesis of Mycobacterium Tuberculosis
Principal Investigator: Sarah K. Parker, MD
Source: National Institutes of Health - 1 K08 AI050646-04
Amount: $560,000
Term: 2002-2007
CD40-CD154 Interactions in Cryptosporidial Immunity
Principal Investigator: Esther Ponnuraj, PhD
Source: National Institutes of Health - R01 A140870-05
Amount: $673,622
Term: 2002-2005
Immune Responses to Varicella Vaccine in HIV-Infected Adults
Principal Investigator: Kathleen Brady, MD
Co-Investigator: Adriana Weinberg, MD
Source: National Institutes of Health - K23RR16116-02
Amount: $754,246
Term: 2000-2005
Epidemiology of Adult Glioma
Principal Investigator: Margaret Wrensch, MD
Co-Investigator: Adriana Weinberg, MD
Source: National Institutes of Health - R01 CA52689
Amount: $8,000,863
Term: 2001-2006
2003-2004
A Double-Blind, Placebo-Controlled, Virologic Efficacy Trial of Pleconaril (VP63843) in the Treatment of Neonates with EV Sepsis Syndrome (Protocol Version 2.0/Version Date 4/25/99)
Principal Investigator: Mark J. Abzug, MD
Source: National Institute of Allergy and Infectious Disease Collaborative Antiviral Study Group, National Institutes of Health
Amount: Per patient enrolled
Term: 1999-ongoing
Safety of Ciprofloxacin in Pediatric Patients
Principal Investigator: Marsha S. Anderson, MD
Source: Bayer Corporation
Amount: Per patient
Term: 2001-present
Denver for Advanced Public Health Preparedness Center
Principal Investigator: Arthur Davidson, MD
Co-Investigator: Marsha S. Anderson, MD
Source: Centers for Disease Control and Prevention - U90/CCU817608
Amount: $12,000
Term: 2000-2003
Apoptotic Signaling in Viral Myocarditis
Principal Investigator: Roberta L. DeBiasi, MD
Source: National Institutes of Health Physician Scientist Award - 1 K08 A152261-01
Amount: $604,800
Term: 2002-2007
Effectiveness of Pneumococcal Conjugate Vaccine in Children
Co-Principal Investigators: Mary P. Glodé, MD, and Ann-Christine Nyquist, MD, MSPH
Source: Centers for Disease Control and Prevention - 2890
Amount: $419,460
Term: 2000-2004
Pertussis Vaccine Effectiveness Study Among Children Aged 6 to 59 Months
Co-Principal Investigators: Mary P. Glodé, MD, and Christine Robinson, PhD
Source: Centers for Disease Control and Prevention - 98B066(N)
Amount: $148,300
Term: 1998-2003
A Double-Blind, Randomized, Controlled Phase III Study to Assess the Prophylactic Efficacy and Safety of Bd-Alum/MPL Vaccine in the Prevention of Genital Herpes Diseases in Young Women Who Are HSV-1 and -2 Seronegative
Principal Investigator: Myron J. Levin, MD
Source: National Institute of Allergy and Infectious Disease and St. Louis University/GlaxoSmithKline
Amount: $974,693/yr
Term: 2002-2006
A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalating, Pilot Study to Assess the Safety of Live, Attenuated Varicella-Zoster Vaccine Given Concomitantly with Recombinant Human Interleukin-12 (rhIL-12) in Healthy Adults 60 to 79 Years of Age
Principal Investigator: Myron J. Levin, MD
Source: Genetics Institute
Amount: $9,126,000
Term: 1999-2004
University of Colorado Center for AIDS Research
Principal Investigator: Robert Schooley, MD
Co-Principal Investigator: Myron J. Levin, MD
Source: National Institute of Allergy and Infectious Disease
Amount: $7,946,900
Term: 2003-2008
Study of the Safety and Efficacy of an Iontophoretic Device to Treat Recurrent Herpes Labialis
Principal Investigator: Myron J. Levin, MD
Source: Klearsen Corporation
Amount: $7,946,900
Term: 2003-2005
Pediatric and Perinatal HIV Clinical Trials
Principal Investigator: Myron J. Levin, MD
Co-Investigator: Elizabeth J. McFarland, MD
Source: Westat and National Institutes of Health, National Institute of Child and Human Development - N01-HD-3-3162
Amount: $5,010,161
Term: 2002-2007
Demonstration Project to Improve Research and Care of HIV-Infected Children
Principal Investigator: Myron J. Levin, MD
Co-Investigator: Elizabeth J. McFarland, MD
Source: Department of Health and Human Services, Health Resources and Services Administration, Ryan White Title IV HIV Program
Amount: $4,437,722
Term: 1995-2004
Expansion of Pediatric ACTU
Principal Investigator: Myron J. Levin, MD
Co-Investigator: Adriana Weinberg, MD
Source: National Institute of Childhood Diseases - U0132915-05
Amount: $4,156,500
Term: 1996-2007
Demonstration Project to Improve Research and Care of HIV-Infected Children
Principal Investigator: Myron J. Levin, MD
Co-Investigator: Elizabeth J. McFarland, MD
Source: Health Resources and Services Administration, Ryan White Title IV HIV Program
Amount: $2,507,595
Term: 2001-2004
Trial of Varicella Vaccine for the Prevention of Herpes Zoster and its Complications
Principal Investigator: Myron J. Levin, MD
Source: National Institute of Allergy and Infectious Disease, Veterans Administration - VA CSP403
Amount: $1,532,185
Term: 1998-2004
Depression and Trial of Varicella Vaccine in the Elderly
Principal Investigator: Myron J. Levin, MD
Source: UCLA Medical Center
Amount: $388,001
Term: 2000-2004
Probe Study to Evaluate the Safety, Tolerability and Immunogenicity of a Process Upgrade Varicella-Zoster Vaccine as a Booster Dose in Previously Vaccinated Adults 60 Years of Age and Older
Principal Investigator: Myron J. Levin, MD
Source: Merck Research Laboratories - Zoster Protocol 005
Amount: $132,000
Term: 1999-2004
Pediatric HIV Clinical Trials Network
Principal Investigator: Myron J. Levin, MD
Co-Investigator: Mark J. Abzug, MD
Source: National Institutes of Health, National Institute of Child Health and Human Development - N01-HD-3-3162
Amount: $117,875
Term: 2002-2004
A Phase III, Open-Labeled, Randomized, Multicenter, Clinical Study of the Safety of a Primary Series of GlaxoSmithKline Biologicals' DTPa-HepB-IPV Candidate Vaccine Coadministered with HibTITER® and Prevnar® to Healthy Infants at 2, 4, and 6 Months of Age as Compared to the Separate Administration of Infanrix® + Engerix-B® + IPOL® + HibTITER® + Prevnar®
Principal Investigator: Myron J. Levin, MD
Source: GlaxoSmithKline Biologicals - 084
Amount: $111,678
Term: 2001-2003
Retrospective Study That Would Evaluate Asthmatic Children Who Had Already Received Varivax® in the Past
Principal Investigator: Myron J. Levin, MD
Source: Merck Research Laboratories
Amount: $69,000
Term: 2003-2006
A Double-Blind, Placebo-Controlled, Randomized Study to Evaluate the Safety, Tolerability and Immunogenicity After One and Two Doses of PHN/Zoster Vaccine
Principal Investigator: Myron J. Levin, MD
Source: Merck Research Laboratories - Zoster Protocol 007
Amount: $54,900
Term: 2001-2004
Phospholipases in the Pathogenesis of Mycobacterium Tuberculosis
Principal Investigator: Sarah K. Parker, MD
Source: National Institutes of Health - 1 K08 AI050646-04
Amount: $560,000
Term: 2002-2007
CD40-CD154 Interactions in Cryptosporidial Immunity
Principal Investigator: Esther Ponnuraj, PhD
Source: National Institutes of Health - R01 A140870-05
Amount: $673,622
Term: 2002-2005
Respiratory Viral Infections in Filipino Children
Principal Investigator: Eric A. F. Simoes, MD
Co-Investigator: Adriana Weinberg, MD
Source: World Health Organization
Amount: $170,000
Term: 2001-2004
Immunogenicity of Influenza Vaccine in Children with Rheumatologic Disorders
Principal Investigator: Jennifer Soep, MD
Co-Investigator: Adriana Weinberg, MD
Source: Pediatric General Clinical Research Center
Amount: $10,000
Term: 2001-2003
Pediatric Pharmacology Research Unit Network
Principal Investigator: Stanley J. Szefler, MD
Co-Principal Investigators: Harley A. Rotbart, MD, and Mark J. Abzug, MD
Co-Investigator: Joseph D. Spahn, MD
Source: National Institutes of Health, National Institute of Childhood Health and Disease - HD37237
Amount: $1,364,175
Term: 1999-2003
Pediatric AIDS Clinical Trials Group
Principal Investigator: Adriana Weinberg, MD
Source: National Institute of Childhood Diseases - N01-HD-33162
Amount: $1,796,322
Term: 1997-2003
Shingles Prevention Study
Principal Investigator: Adriana Weinberg, MD
Source: Veterans Administration - CSP403
Amount: $960,642
Term: 2001-2004
Immune Responses to Varicella Vaccine in HIV-Infected Adults
Principal Investigator: Kathleen Brady, MD
Co-Investigator: Adriana Weinberg, MD
Source: National Institutes of Health - K23RR16116-02
Amount: $754,246
Term: 2000-2005
Epidemiology of Adult Glioma
Principal Investigator: Margaret Wrensch, MD
Co-Investigator: Adriana Weinberg, MD
Source: National Institutes of Health - R01 CA52689
Amount: $8,000,863
Term: 2001-2006
Manufacturing of VZV Antigen
Principal Investigator: Adriana Weinberg, MD
Source: Merck Research Laboratories
Amount: $280,000
Term: 1999-2004
VZV ELISPOT Validation for Studies of VZV-Specific Cell-Mediated Immunity
Principal Investigator: Adriana Weinberg, MD
Source: Merck Research Laboratories
Amount: $224,125
Term: 2001-2004
CMV Immune Reconstruction in AIDS Patients on HAART
Principal Investigator: Adriana Weinberg, MD
Source: National Institutes of Health - 2U01A38858 AACTG 360.06
Amount: $152,000
Term: 2002-2003
Persistence of VZV Immunity in Elderly Recipients of the PHN/Zoster Vaccine
Principal Investigator: Adriana Weinberg, MD
Source: Merck Research Laboratories
Amount: $49,000
Term: 2001-2004
Cell-Mediated Immunity in Herpes Zoster Patients
Principal Investigator: Adriana Weinberg, MD
Source: Merck Research Laboratories
Amount: $48,000
Term: 2001-2004
Kinetics of Cell-Mediated Immune Responses to PHN/Zoster Vaccine
Principal Investigator: Adriana Weinberg, MD
Source: Merck Research Laboratories
Amount: $46,626
Term: 2001-2004
Diagnosis of CMV Infection in Stem Cell Recipients
Principal Investigator: Adriana Weinberg, MD
Source: AmCell
Amount: $20,000
Term: 2002-2004
PCR Diagnosis of Zoster
Principal Investigator: Adriana Weinberg, MD
Source: Merck Research Laboratories
Amount: $15,000
Term: 2001-2003
Evaluation of Directigen EZ Flu A+B Kit
Principal Investigator: Adriana Weinberg, MD
Source: Becton Dickinson
Amount: $10,000
Term: 2002-2003
Flu OIA Evaluation
Principal Investigator: Adriana Weinberg, MD
Source: Biostar
Amount: $10,000
Term: 2002-2003
2001-2002
A Double-Blind, Placebo-Controlled, Virologic Efficacy Trial of Pleconaril (Vp63843) in the Treatment of Infants with Enteroviral Meningitis (Protocol Version 2.0)
Principal Investigator: Mark J. Abzug, MD
Source: National Institute of Allergy and Infectious Disease Collaborative Antiviral Study Group
Amount: Per patient enrolled
Term: 1999-2001
A Double-Blind, Placebo-Controlled, Virologic Efficacy Trial of Pleconaril (Vp63843) in the Treatment of Neonates with EV Sepsis Syndrome (Protocol Version 2.0/Version Date 4/25/99)
Principal Investigator: Mark J. Abzug, MD
Source: National Institute of Allergy and Infectious Disease Collaborative Antiviral Study Group
Amount: Per patient enrolled
Term: 1999-2002
A Double-Blind, Randomized, Placebo-Controlled Safety and Efficacy Trial of Suspension Formulation of Pleconaril in the Treatment of Viral Respiratory Infection in Children Age 2 to 12 Years (Protocol No. 843-051)
Principal Investigator: Mark J. Abzug, MD
Source: Viropharma
Amount: $4,467
Term: 2000-2001
Natural History of Viral Meningitis in Young Children (4 to 7 Years of Age)
Principal Investigator: Mark J. Abzug, MD
Source: Viropharma
Term: 1999-2001
Safety of Ciprofloxacin in Pediatric Patients
Principal Investigator: Marsha S. Anderson, MD
Source: Bayer Corporation
Amount: Per patient
Term: 2001-2002
Immune Responses to Varicella Vaccine in HIV-Infected Adults
Principal Investigator: Kathleen Brady, MD
Co-Investigator: Adriana Weinberg, MD
Source: National Institutes of Health - K23RR16116-02
Amount: $754,246
Term: 2000-2005
Denver for Advanced Public Health Preparedness Center
Principal Investigator: Arthur Davidson, MD
Co-Investigator: Marsha S. Anderson, MD
Source: Centers for Disease Control and Prevention - U90/CCU817608
Amount: $12,000
Term: 2000-2003
Immunologic Aspects of the Pathogenesis of Chronic Sinusitis in Children: A Six-Month Pilot Study
Principal Investigator: Kenny Chan, MD
Co-Investigators: Andrew H. Liu, MD, and Mark J. Abzug, MD
Source: Pediatric General Clinical Research Center
Term: 1999-2001
Apoptotic Signaling in Viral Myocarditis
Principal Investigator: Roberta L. DeBiasi, MD
Source: National Institutes of Health Physician Scientist Award - 1 K08 A152261-01
Amount: $604,800
Term: 2002-2007
Identification and Targeting of Apoptotic Signaling Pathways in Viral Myocarditis
Principal Investigator: Roberta L. DeBiasi, MD
Source: Veterans Administration Research Career Development Award
Amount: $109,500
Term: 2002-2002
Infectious Diseases Society of American Young Investigator Award
Principal Investigator: Roberta L. DeBiasi, MD
Source: Ortho-McNeil Pharmaceuticals
Amount: $80,000
Term: 2000-2002
Effectiveness of Pneumococcal Conjugate Vaccine in Children
Co-Principal Investigators: Mary P. Glodé, MD, and Ann-Christine Nyquist, MD, MSPH
Source: Centers for Disease Control and Prevention - 2890
Amount: $419,460
Term: 2000-2003
Pertussis Vaccine Effectiveness Study Among Children Aged 6 to 59 Months
Co-Principal Investigators: Mary P. Glodé, MD, and Christine Robinson, PhD
Source: Centers for Disease Control and Prevention - 98B066(N)
Amount: $148,300
Term: 1998-2003
Trial of Varicella Zoster Vaccine for the Prevention of Herpes Zoster and Its Complications
Principal Investigator: Anthony R. Hayward, MD, PhD
Source: Merck Research Laboratories
Amount: Per protocol
Term: 1997-2002
A Comparison of the Safety, Tolerability and Immunogenicity of M-M-RTMII Manufactured with Recombinant Human Albumin (rHA) vs. M-M-RTMII Manufactured with Pooled-Donor Human Serum Albumin (HSA) in Healthy Children 12 to18 Months of Age
Principal Investigator: Myron J. Levin, MD
Source: Merck Research Laboratories - Merck 009
Amount: $92,605
Term: 2001-2002
A Double-Blind, Placebo-Controlled, Randomized Study to Evaluate Safety, Tolerability and Immunogenicity After One and Two Doses of PHN/Zoster Vaccine
Principal Investigator: Myron J. Levin, MD
Source: Merck Research Laboratories - Zoster Study 007
Amount: $54,900
Term: 2001-2002
A Phase III, Open-Labeled, Randomized, Multicenter, Clinical Study of the Safety of a Primary Series of GlaxoSmithKline's DTPa-HepB-IPV Candidate Vaccine Coadministered with HibTITER® and Prevnar® to Healthy Infants at 2, 4 and 6 Months of Age as Compared to the Separate Administration of Infanrix® + Engerix-B® + IPOL® + HibTITER® + Prevnar®
Principal Investigator: Myron J. Levin, MD
Source: GlaxoSmithKline - 084
Amount: $111,678
Term: 2001-2003
A Phase 4, Open, Randomized, Controlled, Comparative, Multicenter US Study of the Safety of GlaxoSmithKline's Combination Hepatitis A and Hepatitis B Vaccine (Twinrix®) Administered on a 0, 1, 6 Month Schedule by Intramuscular Injection Compared with Concurrently Administered Monovalent Vaccines (Havrix®) in Healthy Adults 18 Years of Age and Older
Principal Investigator: Myron J. Levin, MD
Source: GlaxoSmithKline
Amount: $168,085
Term: 2001-2002
A Randomized, Double-Blind, Placebo-Controlled Evaluation of Valacyclovir for Prevention of Herpes Simplex Virus Transmission in Heterosexual Couples
Principal Investigator: Myron J. Levin, MD
Source: GlaxoSmithKline - GSK 009
Amount: $50,000
Term: 2001-2002
Expansion of Pediatric AIDS Clinical Trials Unit
Principal Investigator: Myron J. Levin, MD
Co-Investigator: Adriana Weinberg, MD
Source: National Institute of Child Health and Human Development - N01-HD-3-3162
Amount: $21,715/yr
Term: 1995-2001
Expansion of Pediatric ACTU
Principal Investigator: Myron J. Levin, MD
Co-Investigator: Adriana Weinberg, MD
Source: National Institute of Childhood Diseases - U0132915-05
Amount: $4,156,500
Term: 1996-2007
Demonstration Project to Improve Research and Care of HIV-Infected Children
Principal Investigator: Myron J. Levin, MD
Co-Investigator: Elizabeth J. McFarland, MD
Source: Department of Health and Human Services, Health Resources and Services Administration, Ryan White Title IV HIV Program
Amount: $2,507,595
Term: 2001-2004
Depression and Trial of Varicella Vaccine in the Elderly
Principal Investigator: Myron J. Levin, MD
Source: UCLA Medical Center
Amount: $388,001
Term: 2000-2004
National Institute of Child Health and Human Development Pediatric and Perinatal HIV Clinical Trials
Principal Investigator: Myron J. Levin, MD
Co-Investigator: Elizabeth J. McFarland, MD
Source: Westat, National Institute of Child Health and Human Development - No1-HD-3-3162
Amount: $4,953,000
Term: 1996-2002
Probe Study to Evaluate the Safety, Tolerability and Immunogenicity of a Process Upgrade Varicella-Zoster Vaccine as a Booster Dose in Previously Vaccinated Adults 60 Years of Age and Older
Principal Investigator: Myron J. Levin, MD
Source: Merck Research Laboratories - 005 Booster
Amount: $132,000
Term: 1999-2004
Ryan White Title IV HIV Program
Principal Investigator: Myron J. Levin, MD
Co-Investigator: Adriana Weinberg, MD
Source: National Institute of Child Health and Human Development - 5H 12 HA 00070-08
Amount: $30,400/yr
Term: 1995-2001
Ryan White Title IV
Principal Investigator: Myron J. Levin, MD
Co-Investigator: Adriana Weinberg, MD
Source: Department of Health and Human Services, Health Resources and Services Administration - 2H 12 HA 00070-07
Amount: $2,348,000
Term: 2001-2004
Trial of Varicella Vaccine for the Prevention of Herpes Zoster and its Complications (Protocol No. 403)
Principal Investigator: Myron J. Levin, MD
Source: National Institute of Allergy and Infectious Disease, Veterans Administration - VA CSP403
Amount: $1,532,185
Term: 1998-2004
HIV Adherence Services Contract
Principal Investigator: Elizabeth J. McFarland, MD
Source: Colorado Department of Public Health and Environment
Amount: $32,000
Term: 1999-2002
Mechanisms Leading to Decline of HIV-Specific CTL
Principal Investigator: Elizabeth J. McFarland, MD
Source: National Institutes of Health, National Institute of Allergy and Infectious Diseases - A1 45107
Amount: $659,007
Term: 1998-2001
Children's Hospital Immunodeficiency Program, Ryan White Title I Formula Fund
Principal Investigator: Ann-Christine Nyquist, MD, MSPH
Source: Department of Health and Human Services, Health Resources and Services Administration, Ryan White Title I
Amount: $64,422
Term: 2001-2002
Bile Duct Disease in CD154 Deficiency
Principal Investigator: Esther Ponnuraj, PhD
Source: March of Dimes Birth Defects Foundation - 6-FY99-427
Amount: $50,000/yr
Term: 2001-2002
CD40-CD154 Interactions in Cryptosporidial Immunity
Principal Investigator: Esther Ponnuraj, PhD
Source: National Institutes of Health - R21 A140870-04
Amount: $188,750
Term: 2001-2002
CD40-CD154 Interactions in Cryptosporidial Immunity
Principal Investigator: Esther Ponnuraj, PhD
Source: National Institutes of Health - R01 A140870-05
Amount: $673,622
Term: 2002-2005
Respiratory Viral Infections in Filipino Children
Principal Investigator: Eric A. F. Simoes, MD
Co-Investigator: Adriana Weinberg, MD
Source: World Health Organization
Amount: $170,000
Term: 2001-2004
Immunogenicity of Influenza Vaccine in Children with Rheumatologic Disorders
Principal Investigator: Jennifer Soep, MD
Co-Investigator: Adriana Weinberg, MD
Source: Pediatric General Clinical Research Center
Amount: $10,000
Term: 2001-2003
Pediatric Pharmacology Research Unit Network
Principal Investigator: Stanley J. Szefler, MD
Co-Principal Investigators: Harley A. Rotbart, MD, and Mark J. Abzug, MD
Co-Investigator: Joseph D. Spahn, MD
Source: National Institutes of Health, National Institute of Childhood Health and Disease - HD37237
Amount: $1,364,175
Term: 1999-2003
Reovirus-Induced Apoptosis: Veterans Administration Research Enrichment Award Fellow Program - Roberta L. DeBiasi, MD
Principal Investigator: Kenneth L. Tyler, MD
Source: Veterans Administration
Amount: $50,000
Term: 1999-2001
Cell-Mediated Immunity in Herpes Zoster Patients
Principal Investigator: Adriana Weinberg, MD
Source: Merck Research Laboratories
Amount: $48,000
Term: 2001-2004
CMV Immune Reconstruction in AIDS Patients on HAART
Principal Investigator: Adriana Weinberg, MD
Source: National Institutes of Health - 2U01A38858 AACTG 360.06
Amount: $152,000
Term: 2002-2003
CMV Immunology Laboratory
Principal Investigator: Adriana Weinberg, MD
Source: National Institutes of Health
Amount: $18,120
Term: 1998-2001
Diagnosis of CMV Infection in Stem Cell Recipients
Principal Investigator: Adriana Weinberg, MD
Source: AmCell
Amount: $20,000
Term: 2002-2004
Evaluation of Directigen EZ Flu A+B Kit
Principal Investigator: Adriana Weinberg, MD
Source: Becton Dickinson
Amount: $10,000
Term: 2002-2003
Flu OIA Evaluation
Principal Investigator: Adriana Weinberg, MD
Source: Biostar
Amount: $48,000
Term: 1999-2001
Flu OIA Evaluation
Principal Investigator: Adriana Weinberg, MD
Source: Biostar
Amount: $10,000
Term: 2002-2003
In Vitro: Sensitivity of HSV Isolates from Patients Treated with Topical Penciclovir
Principal Investigator: Adriana Weinberg, MD
Source: SmithKline Beecham
Amount: $112,430
Term: 1999-2001
Kinetics of Cell-Mediated Immune Responses to PHN/Zoster Vaccine
Principal Investigator: Adriana Weinberg, MD
Source: Merck Research Laboratories
Amount: $46,626
Term: 2001-2004
Manufacturing of VZV Antigen
Principal Investigator: Adriana Weinberg, MD
Source: Merck Research Laboratories
Amount: $280,000
Term: 1999-2004
Natural History of CMV Infection in AIDS Patients on HAART: Quantitative CMV PCR
Principal Investigator: Adriana Weinberg, MD
Source: National Institutes of Health, National Institute of Allergy and Infectious Disease - U01A38858 AACTG 27360.03
Amount: $92,000
Term: 1999-2002
PCR Diagnosis of Herpes Zoster
Principal Investigator: Adriana Weinberg, MD
Source: Merck Research Laboratories
Amount: $10,000
Term: 1999-2001
PCR Diagnosis of Zoster
Principal Investigator: Adriana Weinberg, MD
Source: Merck Research Laboratories
Amount: $15,000
Term: 2001-2003
Pediatric AIDS Clinical Trials Group Immunology Core Laboratory
Principal Investigators: Adriana Weinberg, MD, and Elizabeth J. McFarland, MD
Source: National Institute of Child Health and Human Development
Amount: $1,050,000
Term: 1997-2002
PACTG
Principal Investigator: Adriana Weinberg, MD
Source: National Institute of Childhood Diseases - N01-HD-33162
Amount: $1,796,322
Term: 1997-2003
Persistence of VZV Immunity in Elderly Recipients of the PHN/Zoster Vaccine
Principal Investigator: Adriana Weinberg, MD
Source: Merck Research Laboratories
Amount: $49,000
Term: 2001-2004
Shingles Prevention Study
Principal Investigator: Adriana Weinberg, MD
Source: Veterans Administration - CSP403
Amount: $960,642
Term: 2001-2004
VZV ELISPOT Validation for Studies of VZV-Specific Cell-Mediated Immunity
Principal Investigator: Adriana Weinberg, MD
Source: Merck Research Laboratories
Amount: $224,125
Term: 2001-2004
Epidemiology of Adult Glioma
Principal Investigator: Margaret Wrensch, MD
Co-Investigator: Adriana Weinberg, MD
Source: National Institutes of Health - R01 CA52689
Amount: $8,000,863
Term: 2001-2006
1999-2000
A Double-Blind, Placebo-Controlled, Virologic Efficacy Trial of Pleconaril in the Treatment of Infants with Enterovirus Meningitis
Principal Investigator: Mark J. Abzug, MD
Source: National Institutes of Health Collaborative Antiviral Study Group
Amount: Per patient enrolled
Term: May 1999-December 2001
A Double-Blind, Placebo-Controlled, Virologic Efficacy Trial of Pleconaril in the Treatment of Neonates with Enterovirus Sepsis Syndrome
Principal Investigator: Mark J. Abzug, MD
Source: National Institutes of Health Collaborative Antiviral Study Group
Amount: Per patient enrolled
Term: May 1999-December 2001
A Natural History Study of Neonates with Enteroviral Sepsis Syndrome
Principal Investigator: Mark J. Abzug, MD
Source: Viropharma, Inc.
Amount: Per patient enrolled
Term: May 2000-December 2000
A Double-Blind, Randomized, Placebo-Controlled Evaluation of Pleconaril in the Prevention of Otitis Media in Children with a History of Otitis Media Following Picornavirus Respiratory Tract Infections
Co-Principal Investigator: Mark J. Abzug, MD
Co-Investigator: Candice Johnson, MD
Source: Viropharma, Inc.
Amount: $2,490
Term: September 1998-December 1999
Randomized, Comparative, Dose-Ranging, Probe Study to Investigate the Safety and Immunogenicity of Heptavalent Pneumococcal Conjugate Vaccine with a New Formulation of Serotype 6B
Co-Principal Investigator: Mark J. Abzug, MD
Co-Investigator: Candice E. Johnson, MD
Source: Merck Research Laboratories
Amount: $33,040
Term: January 1998-September 1999
A Multicenter, Double Blind, Placebo Controlled Trial of Pleconaril in the Treatment of Enteroviral Meningitis in Children and Adolescents
Principal Investigator: Mark J. Abzug, MD
Source: Viropharma, Inc.
Amount: $30,000
Term: May 1998-December 1999
A Multicenter, Double-Blind, Placebo-Controlled Trial of Pleconaril in the Treatment of Enteroviral Meningitis in Adolescents and Adults
Principal Investigator: Mark J. Abzug, MD
Source: Viropharma, Inc.
Amount: $12,000
Term: May 1998-December 1999
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Impact of Inhaled Zanamivir Treatment on Workplace Attendance and Healthcare Outcomes Due to Influenza A and B Infections
Principal Investigator: Mark J. Abzug, MD
Source: Glaxo Wellcome, Inc.
Amount: $2,772
Term: January 1998-June 2000
Open-Label, Multicenter Trial to Evaluate the Safety and Immunogenicity of a Fifth Consecutive Dose (Booster) of CERTIVA in Healthy Children
Principal Investigator: Mark J. Abzug, MD
Source: North American Vaccine, Inc.
Amount: Per patient enrolled
Term: June 1998-December 2000
Evaluation of Safety and Immunogenicity of Tripedia in Children 4 to 6 Years of Age Who Have Received 4 Doses of Tripedia
Principal Investigator: Mark J. Abzug, MD
Source: Pasteur Merieux Connaught
Amount: $15,840
Term: February 1998-December 2000
A Non-Drug Study to Evaluate Pain Assessment Tools in Young Children 4-7 Years of Age with Viral Meningitis
Principal Investigator: Mark J. Abzug, MD
Source: Viropharma, Inc.
Amount: Per patient enrolled
Term: August 1999-December 2000
Pathogenesis of Chronic Sinusitis in Children
Principal Investigator: Kenny Chan, MD
Co-Investigator: Mark J. Abzug, MD
Source: General Pediatric Clinical Research Center
Amount: $13,740
Term: August 1998-February 1999
Immunologic Aspects of Pathogenesis of Chronic Sinusitis in Children: A 6-Month Pilot Study
Principal Investigator: Kenny Chan, MD
Co-Investigator: Mark J. Abzug, MD
Source: The Children's Hospital Research Institute and General Pediatric Clinical Research Center
Amount: $28,590
Term: October 1999-September 2000
Safety and Efficacy of Valacyclovir in Immunocompromised Children with Herpes Zoster Infection, Multicenter Study
Principal Investigator: Marsha S. Anderson, MD
Source: Colorado Department of Health
Amount: Per patient enrolled
Term: 1999-2000
Investigation of the Mechanism of Cell Signaling in Neutrophils
Principal Investigator: Marsha S. Anderson, MD
Source: The Children's Hospital Research Institute
Amount: $70,000
Term: 1999
Infectious Diseases Society of American Young Investigator Award
Principal Investigator: Roberta L. DeBiasi, MD
Source: Ortho-McNeil Pharmaceuticals
Amount: $80,000
Term: July 2000-July 2002
Reovirus-Induced Apoptosis: Veterans Administration Research Enrichment Award Fellow Program - Roberta L. DeBiasi, MD
Principal Investigator: Kenneth L. Tyler, MD
Source: Veterans Administration
Amount: $50,000
Term: July 1999-July 2001
Pertussis Vaccine Effectiveness Study Among Children Aged 6 to 59 Months
Principal Investigator: Mary P. Glodé, MD
Source: Centers for Disease Control and Prevention
Amount: $148,320
Term: 1998-2001
Demonstration Project to Improve Research and Care of HIV-Infected Children
Principal Investigator: Myron J. Levin, MD
Co-Investigator: Elizabeth J. McFarland, MD
Source: Health Resources and Services Administration, Ryan White Title IV HIV Program
Amount: $1,390,897
Term: August 1995-July 2001
Assessment of the Ability of the Live Attenuated Oka/Merck Varicella Vaccine Made in the New Production Facility to Boost Immunity to Varicella in Adults 55 Years of Age and Older
Principal Investigator: Myron J. Levin, MD
Source: Merck Sharp and Dohme Research Laboratories
Amount: $180,000
Term: November 1996-October 1999
Pilot Dose-Ranging Study to Assess the Safety and Tolerability of Live, Attenuated Oka/Merck Varicella-Zoster Vaccine in Healthy, Seropositive Adults 60 Years of Age and Older
Principal Investigator: Myron J. Levin, MD
Source: Merck Sharp and Dohme Research Laboratories
Amount: $107,644
Term: November 1996-October 1999
Pilot Study to Assess the Ability of the Oka/Merck Varicella Vaccine to Boost Immunity to Varicella in Adults 55 Years of Age and Older. Additional Dose of Varicella to Boost CMI
Principal Investigator: Myron J. Levin, MD
Source: Merck Sharp and Dohme Research Laboratories
Amount: $138,150
Term: November 1996-October 1999
Dose Response Study Comparing Varying Dosage Levels of Process Upgrade Varicella Vaccine (PUVV) in Concomitant Use with M-M-RTMII in Healthy Children
Principal Investigator: Myron J. Levin, MD
Source: Merck Sharp and Dohme Research Laboratories
Amount: $52,700
Term: September 1998-February 1999
A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy of SmithKline Beecham Biologicals' Herpes Simplex Candidate Vaccine (gD2t) with MPL and its Efficacy to Prevent Genital Herpes Disease in Healthy HSV Positive or Negative Consorts of Subjects with Genital Herpes Disease
Principal Investigator: Myron J. Levin, MD
Source: SmithKline Beecham Biologicals
Amount: $96,000
Term: July 1996-June 1999
A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy of SmithKline Beecham Biologicals' Herpes Simplex Candidate Vaccine (gD2t) with MPL to Prevent Genital Herpes Disease in Healthy Consorts of Subjects with Genital Herpes Disease
Principal Investigator: Myron J. Levin, MD
Source: SmithKline Beecham Biologicals
Amount: $143,098
Term: July 1996-June 1999
A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalating, Pilot Study to Assess the Safety of Live, Attenuated Varicella-Zoster Vaccine Given Concomitantly with Recombinant Human Interleukin-12 (rhIL-12) in Healthy Adults 60 to 79 Years of Age
Principal Investigator: Myron J. Levin, MD
Source: Genetics Institute
Amount: $96,000
Term: April 1998-March 1999
An Open Study in Healthy Subjects Who Experience Frequent Episodes of Herpes Labialis to Investigate Whether Repeated Treatment with Penciclovir Cream Leads to the Selection of Virus with Reduced Susceptibility to Penciclovir
Principal Investigator: Myron J. Levin, MD
Source: SmithKline Beecham Biologicals
Amount: $177,912
Term: October 1998-September 1999
A Double-Blind, Randomized, Placebo-Controlled Study of RO-64-0796 in the Treatment of Children with Influenza (Protocol No. WV 15758)
Principal Investigator: Myron J. Levin, MD
Source: Roche Pharmaceutical Research
Amount: $49,670
Term: October 1998-September 1999
Pilot Study of the Safety, Tolerability and Immunogenicity of a Live Attenuated Varicella Vaccine (VARIVAXTM) in Asthmatic Subjects 12 Months to 18 Years of Age Who Are Receiving Chronic Inhaled Corticosteroids
Principal Investigator: Myron J. Levin, MD
Source: Merck Sharp and Dohme Research Laboratories
Amount: $202,900
Term: October 1998-September 1999
National Institute of Child Health and Human Development Pediatric and Perinatal HIV Clinical Trials
Principal Investigator: Myron J. Levin, MD
Co-Investigator: Elizabeth J. McFarland, MD
Source: Westat National Institute of Child and Human Development - N01-HD-3-3162
Amount: $3,138,000
Term: September 1996-October 2000
Trial of Varicella Vaccine for the Prevention of Herpes Zoster and its Complications (Protocol No. 403)
Principal Investigator: Myron J. Levin, MD
Source: National Institute of Allergy and Infectious Disease, Veterans Administration
Amount: $1,532,185
Term: December 1998-December 2004
A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalating, Pilot Study to Assess the Safety of Live, Attenuated Varicella-Zoster Vaccine Given Concomitantly with Recombinant Human Interleukin-12 (rhIL-12) in Healthy Adults 60 to 79 Years of Age
Principal Investigator: Myron J. Levin, MD
Source: Genetics Institute
Amount: $96,000
Term: April 1998-March 1999
Phase II Dose Comparison Study to Evaluate the Safety and Immunogenicity of MEDI-517 and Phase I Study to Evaluate the Safety and Immunogenicity of MEDI-517 in Healthy Adults Who Are HPV-16 or HPV-18 DNA Positive
Principal Investigator: Myron J. Levin, MD
Source: MedImmune, Inc.
Amount: $157,047
Term: November 1999-October 2000
Study of Immunogenicity of Pilot Manufacturing Material of HPV 16 Virus-Like Particles (VLP) Vaccine in 18-25 Year Old Women
Principal Investigator: Myron J. Levin, MD
Source: Merck Sharp and Dohme Research Laboratories
Amount: $94,320
Term: October 1998-September 2000
Pilot Study of the Safety, Tolerability and Immunogenicity of a Live Attenuated Varicella Vaccine (VARIVAXTM) in Asthmatic Subjects 12 Months to 18 Years of Age Who Are Receiving Chronic Inhaled Corticosteroids
Principal Investigator: Myron J. Levin, MD
Source: Merck Sharp and Dohme Research Laboratories
Amount: $202,900
Term: September 1999-October 2000
A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy of SmithKline Beecham Biologicals' Herpes Simplex candidate vaccine (gD2t) with MPL and its Efficacy to Prevent Genital Herpes Disease in Healthy HSV Positive or Negative Consorts of Subjects with Genital Herpes Disease (Protocol No. 017)
Principal Investigator: Myron J. Levin, MD
Source: SmithKline Beecham Biologicals
Amount: $96,000
Term: July 1996-June 1999
A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy of SmithKline Beecham Biologicals' Herpes Simplex candidate vaccine (gD2t) with MPL to Prevent Genital Herpes Disease in Healthy Consorts of Subjects with Genital Herpes Disease (Protocol No. 007)
Principal Investigator: Myron J. Levin, MD
Source: SmithKline Beecham Biologicals
Amount: $143,098
Term: July 1996-June 1999
Ryan White Title IV HIV Program
Principal Investigator: Myron J. Levin, MD
Co-Investigator: Adriana Weinberg, MD
Source: National Institute of Child Health and Human Development
Amount: $30,400/yr
Term: August 1995-July 2001
Expansion of Pediatric AIDS Clinical Trials Unit
Principal Investigator: Myron J. Levin, MD
Co-Investigator: Adriana Weinberg, MD
Source: National Institute of Child Health and Human Development
Amount: $21,715/yr
Term: November 1995-October 2001
Ryan White Title I Funds for HIV Care
Principal Investigator: Elizabeth J. McFarland, MD
Source: Mayor's Office of HIV Resources
Amount: $35,500
Term: March 1998-February 1999
V-beta Repertoire Assay Development
Principal Investigator: Elizabeth J. McFarland, MD
Source: Social and Scientific Systems, Inc.
Amount: $25,000
Term: April 1998-April 1999
Mechanisms Leading to Decline of HIV-Specific CTL
Principal Investigator: Elizabeth J. McFarland, MD
Source: National Institutes of Health, National Institute of Allergy and Infectious Diseases
Amount: $659,007
Term: August 1998-July 2001
Children's Hospital Immunodeficiency Program, Ryan White Title I Formula Fund
Principal Investigator: Ann-Christine Nyquist, MD, MSPH
Source: Health Resources and Services Administration, Ryan White Title I
Amount: $3,763
Term: March 1998-February 1999
Children's Hospital Immunodeficiency Program, Ryan White Title I Formula Fund
Principal Investigator: Ann-Christine Nyquist, MD, MSPH
Source: Health Resources and Services Administration, Ryan White Title I
Amount: $46,450
Term: March 2000-March 2001
CHIP Youth Project
Principal Investigator: Ann-Christine Nyquist, MD, MSPH
Source: Gill Foundation
Amount: $18,500
Term: January 1998-January 1999
Natural History of Pre-Diabetic Autoimmunity - Lab
Principal Investigator: Harley A. Rotbart, MD
Source: National Institutes of Health
Amount: $15,000
Term: 1998-1999
Enterovirus Research
Principal Investigator: Harley A. Rotbart, MD
Source: ViroPharma Research
Amount: $73,000
Term: 1998-1999
Enterovirus Research
Co-Principal Investigator: Harley A. Rotbart, MD
Source: Pharmacia and Upjohn
Amount: $55,000
Term: 1998-1999
Enterovirus Research
Principal Investigator: Harley A. Rotbart, MD
Source: Specialty Laboratories
Amount: $24,000
Term: 1998-1999
Enterovirus Research
Principal Investigator: Harley A. Rotbart, MD
Source: The Children's Hospital, Denver
Amount: $25,000
Term: 1998-1999
Pediatric Pharmacology Research Unit Network
Principal Investigator: Stanley J. Szefler, MD
Co-Principal Investigators: Harley A. Rotbart, MD, and Mark J. Abzug, MD
Source: National Institutes of Health
Amount: $1,364,175
Term: January 1999-December 2003
Pediatric AIDS Clinical Trials Group CMV Laboratory
Principal Investigator: Adriana Weinberg, MD
Source: National Institute of Allergy and Infectious Disease
Amount: $37,500/yr
Term: 1997-2000
Pediatric AIDS Clinical Trials Group Immunology Core Laboratory
Principal Investigators: Adriana Weinberg, MD, and Elizabeth J. McFarland, MD
Source: National Institute of Child Health and Human Development
Amount: $350,000/yr
Term: 1997-2001
Pediatric AIDS Clinical Trials Group CMV Immunity Laboratory
Principal Investigator: Adriana Weinberg, MD
Source: National Institute of Allergy and Infectious Disease
Amount: $18,120
Term: 1998-2000
Topical Treatment of HSV
Principal Investigator: Adriana Weinberg, MD
Source: SmithKline Beacham
Amount: $450,000
Term: 1999-2001
Varicella Zoster Immunity in AIDS
Principal Investigator: Adriana Weinberg, MD
Source: National Institutes of Health
Amount: $29,000
Term: 1998-2000
Quantitative CMV PCR
Principal Investigator: Adriana Weinberg, MD
Source: National Institute of Allergy and Infectious Disease
Amount: $92,000
Term: 1999-2002
|
|
